News

Evolve BioSystems Inc., a spin-off from the UC Davis Foods For Health Institute, that is developing novel solutions to restore and maintain a healthy newborn gut microbiome, announced that it has completed a $20 million Series B financing to fund the commercialization of its initial products.

The company is developing activated probiotic and prebiotic products based on research that shows the infant gut microbiome plays a critical role in the development of a healthy immune system and early metabolic programing as well as meeting the infant's dietary needs.

Evolve’s founding team, which includes UC Davis faculty members Bruce German, David Mills, Carlito Lebrilla and Daniela Barile, along with previous UC Davis scientist Dr. Samara Freeman, has been conducting research at the forefront of infant nutritional health for over a decade, with a focus on understanding the key role of breast milk in creating a healthy intestinal tract.

The company states the funding will support ongoing clinical activities, operational expansion, and the launch of the initial commercial products. It will also support the development and commercialization of additional animal health products, which aim to restore the balance of nursing animals' microbiomes.